Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients.
Chronic hepatitis B
Hepatitis B core-related antigen
Hepatitis B e antigen-negative
Hepatitis B surface antigen
Nucleos(t)ids analogues
Pegylated-interferon
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Nov 2020
27 Nov 2020
Historique:
received:
02
06
2020
revised:
23
06
2020
accepted:
04
09
2020
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss. To evaluate if the addition of pegylated interferon (Peg-IFN) could decrease HBsAg and hepatitis B core-related antigen (HBcrAg) levels and increase HBsAg loss rate in patients under NAs therapy. Prospective, non-randomized, open-label trial evaluating the combination of Peg-IFN 180 µg/week plus NAs during forty-eight weeks Sixty-five patients were enrolled, 61% receiving tenofovir and 33% entecavir. Thirty-six (55%) were included in Peg-IFN-NA group and 29 (44%) in NA group. After matching by age and treatment duration, baseline HBsAg levels were comparable between groups (3.1 The addition of Peg-IFN to NAs caused a greater and faster decrease of HBsAg levels compared to NA therapy. Side effects of Peg-IFN can limit its use in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss.
AIM
OBJECTIVE
To evaluate if the addition of pegylated interferon (Peg-IFN) could decrease HBsAg and hepatitis B core-related antigen (HBcrAg) levels and increase HBsAg loss rate in patients under NAs therapy.
METHODS
METHODS
Prospective, non-randomized, open-label trial evaluating the combination of Peg-IFN 180 µg/week plus NAs during forty-eight weeks
RESULTS
RESULTS
Sixty-five patients were enrolled, 61% receiving tenofovir and 33% entecavir. Thirty-six (55%) were included in Peg-IFN-NA group and 29 (44%) in NA group. After matching by age and treatment duration, baseline HBsAg levels were comparable between groups (3.1
CONCLUSION
CONCLUSIONS
The addition of Peg-IFN to NAs caused a greater and faster decrease of HBsAg levels compared to NA therapy. Side effects of Peg-IFN can limit its use in clinical practice.
Identifiants
pubmed: 33312431
doi: 10.4254/wjh.v12.i11.1076
pmc: PMC7701972
doi:
Types de publication
Clinical Trial
Langues
eng
Pagination
1076-1088Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Authors declare no conflict-of-interest.
Références
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Hepatol Int. 2013 Mar;7(1):88-97
pubmed: 23518903
J Gastroenterol Hepatol. 2011 Apr;26(4):628-38
pubmed: 21323729
N Engl J Med. 2004 Sep 16;351(12):1206-17
pubmed: 15371578
J Infect Dis. 2011 Aug 1;204(3):415-8
pubmed: 21742840
Gastroenterology. 2016 Jan;150(1):134-144.e10
pubmed: 26453773
Hepatology. 2013 Sep;58(3):923-31
pubmed: 23468172
Antiviral Res. 2014 Feb;102:35-43
pubmed: 24316030
J Hepatol. 2019 Apr;70(4):615-625
pubmed: 30529504
Hepatology. 2013 Sep;58(3):872-80
pubmed: 23553752
Hepatology. 2001 Jul;34(1):194-203
pubmed: 11431751
Gastroenterology. 2012 Oct;143(4):963-73.e9
pubmed: 22796241
J Hepatol. 2011 Feb;54(2):209-18
pubmed: 21095036
J Hepatol. 2012 Jul;57(1):167-85
pubmed: 22436845
J Clin Microbiol. 2007 Dec;45(12):3942-7
pubmed: 17942661
J Clin Virol. 2013 Dec;58(4):713-7
pubmed: 24183313
J Clin Virol. 2012 May;54(1):93-5
pubmed: 22365367
Hepatology. 2013 Mar;57(3):890-6
pubmed: 22473858
J Gastroenterol Hepatol. 2017 Oct;32(10):1746-1753
pubmed: 28201854
J Viral Hepat. 2009 Jan;16(1):36-44
pubmed: 18673426
Lancet. 2013 Feb 9;381(9865):468-75
pubmed: 23234725
Sci Rep. 2017 Dec;7(1):173
pubmed: 28282964
J Hepatol. 2014 Jan;60(1):62-8
pubmed: 24012614
Hepatology. 2006 Sep;44(3):675-84
pubmed: 16941693
J Hepatol. 2014 Sep;61(3):515-22
pubmed: 24798617
Gastroenterology. 2012 Sep;143(3):629-636.e1
pubmed: 22659218
J Hepatol. 2014 Dec;61(6):1228-37
pubmed: 25046847
Liver Int. 2011 Aug;31(7):971-9
pubmed: 21054768
Hepatology. 2016 Jan;63(1):284-306
pubmed: 26566246
PLoS One. 2017 Nov 30;12(11):e0188303
pubmed: 29190670
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188
pubmed: 28404133